Δεκ272013Βιβλιογραφικά δεδομέναOff-Therapy Durability of Response to Entecavir Therapy in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Κατηγορία Βιβλιογραφικά δεδομένα27 Δεκεμβρίου 2013 Μοιραστείτε το! Share on FacebookShare on Facebook Share on XShare on X Share on LinkedInShare on LinkedIn Share on WhatsAppShare on WhatsApp Post navigationΠροηγούμενοPrevious post:Incidence of Colorectal Cancer After Liver Transplantation for Primary Sclerosing Cholangitis: A Systematic Review and Meta-AnalysisΕπόμενοNext post:Conversions from Prograf to Advagraf in Adolescents with stable liver transplantsΣχετικά ΆρθραThe burden of extrahepatic organ failures in European patients with cirrhosis15 Δεκεμβρίου 2025Linerixibat in patients with primary biliary cholangitisand cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial28 Νοεμβρίου 2025Sex and body size disparities under MELD 3.0: Evaluation of persisting gaps in liver transplant access16 Νοεμβρίου 2025Prognostic implications of recompensation of decompensated cirrhosis after SVR in patients with hepatitis C6 Νοεμβρίου 2025Meta- Analysis: Comparison of Living Versus Deceased Liver Transplantation for Primary Sclerosing Cholangitis4 Νοεμβρίου 2025Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab27 Οκτωβρίου 2025
Linerixibat in patients with primary biliary cholangitisand cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial28 Νοεμβρίου 2025
Sex and body size disparities under MELD 3.0: Evaluation of persisting gaps in liver transplant access16 Νοεμβρίου 2025
Prognostic implications of recompensation of decompensated cirrhosis after SVR in patients with hepatitis C6 Νοεμβρίου 2025
Meta- Analysis: Comparison of Living Versus Deceased Liver Transplantation for Primary Sclerosing Cholangitis4 Νοεμβρίου 2025
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab27 Οκτωβρίου 2025
